We’re immensely excited for the first Advocate Development Programme (ADP) specifically developed for patient advocates for myeloproliferative neoplasms.
This training programme is designed to enable the participants to effectively advocate on behalf of their patient community on a political and societal level. Important topics are understanding clinical research and development, mechanisms of accessing diagnostics and drugs. Interaction with stakeholders such as clinicians and industry partners and the basics of evidence-based advocacy are an important part of the programme.
The monthly webinars are online sessions, with duration of 1.5 hours where each participant is able to learn from presentation by at least one expert speaker and a discussion amongst all participants to solidify and understand the learning objectives, and raise questions.